



Unaudited Condensed Consolidated Interim Financial Statements
For the three months ended March 31, 2022 and 2021

Table of Contents

Unaudited consolidated interim statements of financial position	1
Unaudited consolidated interim statements of operations and comprehensive income	2
Unaudited consolidated interim statements of changes in shareholders' equity	3
Unaudited consolidated interim statements of cash flows.....	4
Notes to the unaudited condensed consolidated interim financial statements	5-13

Jamieson Wellness Inc.
Unaudited Consolidated Interim Statements of Financial Position
In thousands of Canadian dollars as at

	<u>Notes</u>	<u>March 31, 2022</u>	<u>December 31, 2021</u>
Assets			
Current assets			
Cash		5,432	6,775
Accounts receivable	3	90,219	104,186
Inventories	4	131,869	119,006
Derivatives	9	5,378	2,149
Prepaid expenses and other current assets		5,064	5,029
		237,962	237,145
Non-current assets			
Property, plant and equipment		97,856	96,977
Goodwill		122,975	122,975
Intangible assets		191,733	192,676
Deferred income tax		2,768	2,702
Total assets		653,294	652,475
Liabilities			
Current liabilities			
Accounts payable and accrued liabilities		74,638	74,533
Income taxes payable		3,458	2,896
Derivatives	9	3,122	3,317
Current portion of other long-term liabilities		2,850	2,876
		84,068	83,622
Long-term liabilities			
Long-term debt	5	140,055	149,125
Post-retirement benefits		3,629	3,544
Deferred income tax		54,904	53,291
Other long-term liabilities		20,126	20,872
Total liabilities		302,782	310,454
Shareholders' equity			
Share capital	6	269,604	268,214
Contributed surplus		15,706	14,786
Retained earnings		62,673	58,998
Accumulated other comprehensive income		2,529	23
Total shareholders' equity		350,512	342,021
Total liabilities and shareholders' equity		653,294	652,475

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Approved on behalf of the Board:

Steve Spooner
Director

David Williams
Director

Jamieson Wellness Inc.**Unaudited Consolidated Interim Statements of Operations and Comprehensive Income**

In thousands of Canadian dollars, except share and per share amounts

	Notes	Three months ended March 31,	
		2022	2021
Revenue	10, 11	103,675	98,270
Cost of sales		65,728	64,382
Gross profit		37,947	33,888
Selling, general and administrative expenses		21,620	20,766
Share-based compensation	7	1,142	2,602
Earnings from operations		15,185	10,520
Foreign exchange loss		463	16
Interest expense and other financing costs	8	1,278	1,415
Earnings before income taxes		13,444	9,089
Provision for income taxes		3,703	2,953
Net earnings		9,741	6,136
Unrealized gain on amounts to be reclassified net of realized gains on amounts reclassified to net earnings	9	3,423	577
Income tax		(907)	(153)
Total other comprehensive income		2,516	424
Comprehensive income		12,257	6,560
Income per share attributable to common shareholders:	12		
Basic, earnings per share		0.24	0.15
Diluted, earnings per share		0.23	0.15
Weighted average number of shares:	12		
Basic		40,442,265	39,889,792
Diluted		41,731,184	41,507,592

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Jamieson Wellness Inc.
Unaudited Consolidated Interim Statements of Changes in Shareholders' Equity
In thousands of Canadian dollars

	<u>Notes</u>	<u>Share capital</u>	<u>Contributed surplus</u>	<u>Retained earnings</u>	<u>Accumulated other comprehensive income</u>	<u>Total shareholders' equity</u>
As at December 31, 2021		268,214	14,786	58,998	23	342,021
Net earnings for the period		-	-	9,741	-	9,741
Issuance of treasury shares	6	1,390	(211)	-	-	1,179
Common share dividend (\$0.15 per share)		-	-	(6,066)	-	(6,066)
Other comprehensive income		-	-	-	2,516	2,516
Currency translation adjustment		-	-	-	(10)	(10)
Share-based compensation	7	-	1,131	-	-	1,131
As at March 31, 2022		269,604	15,706	62,673	2,529	350,512

		<u>Share capital</u>	<u>Contributed surplus</u>	<u>Retained earnings</u>	<u>Accumulated other comprehensive loss</u>	<u>Total shareholders' equity</u>
As at December 31, 2020		255,795	12,986	29,023	(5,402)	292,402
Net earnings for the period		-	-	6,136	-	6,136
Issuance of treasury shares	6	2,502	(463)	-	-	2,039
Common share dividend (\$0.125 per share)		-	-	(4,984)	-	(4,984)
Other comprehensive income		-	-	-	424	424
Currency translation adjustment		-	-	-	(16)	(16)
Share-based compensation	7	-	2,494	-	-	2,494
As at March 31, 2021		258,297	15,017	30,175	(4,994)	298,495

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Jamieson Wellness Inc.
Unaudited Consolidated Interim Statements of Cash Flows
In thousands of Canadian dollars

	Notes	Three months ended March 31,	
		2022	2021
Cash provided by (used in)			
Operating activities			
Net earnings		9,741	6,136
Items not affecting cash			
Depreciation of property, plant, and equipment and right-of-use assets		2,658	2,396
Amortization of intangible assets		1,058	1,053
Deferred income taxes		640	(154)
Share-based compensation	7	1,131	2,494
Others		78	4
Net change in non-cash working capital		1,782	(16,993)
		17,088	(5,064)
Investing activities			
Additions to property, plant and equipment, net		(3,541)	(3,266)
Acquisition of intangible assets		(115)	(340)
		(3,656)	(3,606)
Financing activities			
Proceeds from credit facilities	5	10,000	21,789
Repayment to credit facilities	5	(19,070)	(1,789)
Payment of lease liabilities		(818)	(785)
Exercise of stock options and ESPP	6	1,179	2,039
Dividends to common shareholders		(6,066)	(4,984)
		(14,775)	16,270
(Decrease) Increase in cash		(1,343)	7,600
Cash - Beginning of the period		6,775	1,166
Cash - End of the period		5,432	8,766
Supplemental disclosure			
Amount of income taxes paid		2,541	6,000
Amount of interest paid		1,325	903

(see the accompanying notes to the unaudited condensed consolidated interim financial statements)

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three months ended March 31, 2022 and 2021

1. Company overview

1.1 Description of the business and consolidated financial statements

Jamieson Wellness Inc. (“Jamieson” or the “Company”) is a Canadian public company with common shares (“Common Shares”) listed on the Toronto Stock Exchange under the stock symbol “JWEL”.

The unaudited condensed consolidated interim financial statements of Jamieson and its subsidiaries for the three months ended March 31, 2022 (the “Interim Financial Statements”) were authorized for issue by the Board of Directors of the Company on May 4, 2022. Jamieson is a company continued under the *Business Corporations Act* (Ontario) and resident in Canada. Jamieson’s registered office is located at 66 Wellington Street West, Suite 5300, TD Bank Tower, Toronto, ON, M5K 1E6.

The Company has manufacturing facilities located in Windsor, Ontario and in Toronto, Ontario and is principally engaged in the manufacturing, development, distribution, sales and marketing of branded and customer branded health products for humans including vitamins, herbal and mineral nutritional supplements.

1.2 Subsidiaries

The table below provides a summary of the Company’s subsidiaries. Unless otherwise stated, the subsidiaries as listed below have share capital consisting solely of common shares, which are held directly or indirectly by the Company.

As at Entity	March 31, 2022 %	December 31, 2021 %	Principal Place of Operations
Jamieson Laboratories Ltd.	100	100	Canada
International Nutrient Technologies Limited	100	100	Canada
Body Plus Nutritional Products Inc.	100	100	Canada
Jamieson Health Products (Shanghai) Co., Ltd.	100	100	China
Jamieson Health Products Australia Pty Ltd.	100	100	Australia
Jamieson Health Products UK Ltd.	100	100	United Kingdom
Jamieson Health Products USA Ltd.	100	100	United States of America
Jamieson Health Products Netherlands B.V.	100	100	Netherlands

2. Summary of significant accounting policies

2.1 Basis of preparation and statement of compliance

The Interim Financial Statements have been prepared in accordance with IAS 34, “Interim Financial Reporting”. They do not include all of the information required for full annual financial statements and should be read in conjunction with the consolidated financial statements for the year ended December 31, 2021 (the “Annual Financial Statements”). The Interim Financial Statements have been prepared using the same accounting policies as disclosed in the Annual Financial Statements. The Interim Financial Statements are presented in Canadian dollars and all values are rounded to the nearest thousand (\$000), except share and per share amounts and when otherwise indicated.

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three months ended March 31, 2022 and 2021

3. Accounts receivable

As at	March 31, 2022	December 31, 2021
	\$	\$
Trade	89,295	103,623
Other miscellaneous receivables	1,027	666
Allowance for expected credit losses	(103)	(103)
	90,219	104,186

The Company determines the allowance based on lifetime expected credit losses at each reporting date.

4. Inventories

As at	March 31, 2022	December 31, 2021
	\$	\$
Raw material and packaging	50,736	46,750
Bulk product and work in process	22,883	21,897
Packaged finished goods	61,348	53,204
Inventory provision	(3,098)	(2,845)
	131,869	119,006

An inventory provision is estimated by management based on historical sales, inventory aging and expiry, and expected future sales and is included in cost of sales. Subsequent changes to the provision are recorded in cost of sales in the unaudited consolidated interim statements of operations and comprehensive income.

5. Long-term debt

On September 27, 2019, Jamieson Laboratories Ltd. (“JLL”) amended and restated its credit agreement to add Jamieson Health Products USA Ltd. (collectively with JLL the “Borrowers”) as a co-borrower and to provide a secured revolving facility of \$275,000 (including a \$10,000 swingline facility) with the option to increase the revolving facility by \$200,000 (collectively, the “Credit Facilities”). The Credit Facilities mature on September 27, 2024 with the outstanding principal repayable in full on this date.

The table below illustrates the drawings and repayments applied against the Credit Facilities.

	Three months ended March 31,	
	2022	2021
	\$	\$
<u>Credit Facilities</u>		
<i>Drawings</i>	10,000	21,789
<i>Repayments</i>	(19,070)	(1,789)
	(9,070)	20,000

For the three months ended March 31, 2022, the weighted average interest rate on the Credit Facilities was 3.0% (2021 – 2.8%).

The Credit Facilities are collateralized by security agreements and first charges over the assets including property, plant and equipment and intellectual property of the Borrowers and certain other subsidiaries of JLL, subject to permitted liens.

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three months ended March 31, 2022 and 2021

Under the terms of the Credit Facilities, the Borrowers are subject to restrictive covenants and must maintain an interest coverage ratio of not less than 3.00:1.00 and a leverage ratio not greater than 4.00:1.00. The Borrowers are in compliance with all covenants as at the date of the Interim Financial Statements.

6. Share capital

	Common Shares	
	#	\$
As at December 31, 2021	40,406,940	268,214
Exercise of share-based awards	42,134	1,269
Employee stock purchase plan	3,619	121
As at March 31, 2022	40,452,693	269,604

	Common Shares	
	#	\$
As at December 31, 2020	39,872,912	255,795
Exercise of share-based awards	105,962	2,370
Employee stock purchase plan	3,887	132
As at March 31, 2021	39,982,761	258,297

As at March 31, 2022 and 2021, the authorized share capital consisted of:

- a) Unlimited number of Common Shares. The holders of Common Shares are entitled to receive dividends as declared from time to time, and are entitled to one vote per share at meetings of the Company.
- b) Unlimited number of Preference Shares, issuable in series.

7. Share-based compensation

Senior employees and directors' plan

The Company has an equity-based compensation plan providing for the issuance of securities under which grants will be made by the Company. Under the long-term incentive plan, the Board of Directors, at its discretion may grant share options, restricted shares, restricted share units in the form of time-based restricted share units ("RSUs"), performance-based share units ("PSUs"), deferred share units ("DSUs"), and stock appreciation rights. The awards are settled in Common Shares with a cash settlement alternative available to the Company.

A summary of the status of the Company's outstanding share-based awards and changes during the three months ended March 31, 2022 and year ended December 31, 2021 is presented below:

	March 31, 2022				December 31, 2021			
	Options (number of shares)	PSUs (number of shares)	RSUs (number of shares)	DSUs (number of shares)	Options (number of shares)	PSUs (number of shares)	RSUs (number of shares)	DSUs (number of shares)
Outstanding awards, beginning of period	2,576,838	198,036	62	15,563	2,546,553	256,894	9,000	-
Granted	416,679	52,224	765	12,420	461,566	39,909	62	17,016
Exercised	(42,134)	-	-	-	(412,571)	(95,706)	(9,000)	-
Forfeited	(7,598)	-	-	-	(18,710)	(3,061)	-	(1,453)
Outstanding awards, end of period	2,943,785	250,260	827	27,983	2,576,838	198,036	62	15,563
Awards exercisable, end of period	1,735,943	-	-	-	1,520,112	-	-	-

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three months ended March 31, 2022 and 2021

The Company's share-based compensation expense for the three months ended March 31, 2022 is \$1,142 (2021 - \$2,602), of which \$1,131 (2021 - \$2,494) is classified as contributed surplus in the Company's consolidated financial statements and \$11 (2021 - \$108) is related to employment taxes paid on exercise of options. In the first quarter of 2021, the Company accelerated \$1,498 of share-based compensation expense in relation to the Company's CEO transition.

8. Interest expense and other financing costs

	Three months ended March 31,	
	2022	2021
	\$	\$
Interest on debt and borrowings	1,061	1,181
Interest on lease liabilities	217	234
	<u>1,278</u>	<u>1,415</u>

9. Financial instruments and risk management activities

Financial instruments

Fair value measurement

All derivative instruments have been classified as Level 2 in the fair value hierarchy.

The fair values and notional amounts of derivative financial instruments shown below are as at:

	March 31, 2022				December 31, 2021			
	Notional		Fair Value		Notional		Fair Value	
	Amount	Amount	Asset	Liability	Amount	Amount	Asset	Liability
	\$CAD	\$USD	\$	\$	\$CAD	\$USD	\$	\$
Foreign currency forward contract designated as hedging instruments (forecast purchases)	-	49,000	-	(3,122)	-	60,000	-	(3,317)
Foreign currency forward contract designated as hedging instruments (forecast sales)	-	(36,000)	855	-	-	(45,000)	264	-
Interest rate swaps designated as hedging instruments	120,000	-	4,523	-	130,000	-	1,885	-
	<u>120,000</u>	<u>13,000</u>	<u>5,378</u>	<u>(3,122)</u>	<u>130,000</u>	<u>15,000</u>	<u>2,149</u>	<u>(3,317)</u>

On June 5, 2020, the Company entered into an interest rate swap with an effective date of October 1, 2020 to September 27, 2024 with a notional principal of \$140,000 and an annual amortization of \$10,000 on the first business day of each year. The notional principal of the interest rate swap is \$120,000 as at the end of this reporting period. The interest rate swap is a derivative measured at fair value and meets hedge accounting requirements.

The carrying values of financial assets and liabilities measured at amortized cost (excluding long-term debt) approximate their fair values due to their short-term nature.

The carrying value of long-term debt as at March 31, 2022 and December 31, 2021 approximates their fair value. The fair value of the Company's long-term debt was estimated based on discounted future cash flows using current rates for similar financial instruments subject to similar risks and maturities. The fair value of long-term debt is considered a Level 2 fair value measurement.

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three months ended March 31, 2022 and 2021

For the three month period ended March 31, 2022 there were no transfers between levels.

Financial instrument risk management objectives and policies

The Company is exposed to credit risk, market risk and liquidity risk. The Company's senior management oversees the management of these risks. The Company's financial instruments and policies for managing these risks are detailed below.

Credit risk

Credit risk refers to the risk that a counterparty will default on its contractual obligations, resulting in financial loss to the Company. The Company is exposed to credit risk from its customers (primarily related to trade accounts receivable) in the normal course of business. The Company has adopted a policy of only dealing with creditworthy counterparties. To mitigate this risk, the Company carries out regular credit evaluations and purchases credit insurance for international customers, where appropriate, as a means of mitigating the risk of financial loss from defaults.

The Company is also exposed to counterparty credit risk inherent in its financing activities, trade receivable insurance, foreign currency derivatives and interest rate derivatives. The Company has assessed these risks as minimal.

Market risk

Foreign exchange risk

Foreign exchange risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates. The Company's exposure to the risk of changes in foreign exchange rates relates primarily from transactions in U.S. dollars such as a portion of trade accounts payable, trade accounts receivable and cash.

The Company uses foreign exchange forward contracts to manage foreign exchange transaction exposure. As of March 31, 2022, \$64,321 (December 31, 2021 - \$79,317) of anticipated foreign currency denominated purchases have been hedged and \$45,815 (December 31, 2021 - \$57,275) of anticipated foreign currency denominated sales have been hedged with underlying foreign exchange forward contracts settling at various dates in the 9 months proceeding the unaudited consolidated interim statement of financial position date.

Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company's accounts receivable and accounts payable are non-interest bearing. The Company's exposure to the risk of changes in market interest rates arises from long-term debt obligations issued at fixed rates that create fair value interest rate risk and variable rate borrowings that create cash flow interest rate risk.

The Company manages its interest rate risk by having a balanced portfolio of fixed and variable rate loans and borrowings. To further reduce the long-term interest rate exposure and gain predictability over future cash flows, the Company uses interest rate swaps, in which it agrees to exchange, at specified intervals, the difference between fixed and variable rate interest amounts calculated by reference to an agreed-upon notional principal amount.

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three months ended March 31, 2022 and 2021

With all other variables held constant, the sensitivity to a reasonably possible change in interest rates on floating rate borrowings of the Company would have the following impact to net earnings before taxes:

	Increase/decrease in basis points	Effect on profit before tax
	+/-	\$
Three months ended March 31, 2021	100	58
Three months ended March 31, 2020	100	99

Changes in market interest rates cause the fair value of long-term debt with fixed interest rates to fluctuate but do not affect net earnings, as the Company's debt is carried at amortized cost and the carrying value does not change as interest rates change.

Commodity price risk

The Company is exposed to price risk related to purchases of certain commodities used as raw materials. The Company may use fixed price contracts with suppliers to mitigate commodity price risk. Concentration in any one raw material is not significant to the Company.

Liquidity risk

Liquidity risk is the risk the Company will not be able to meet its financial obligations associated with financial liabilities. The Company is exposed to this risk mainly in respect of its accounts payable and accrued liabilities, various long-term debt agreements, obligations under its post-retirement benefits plan and lease commitments. The Company manages its liquidity risk through continuous monitoring of its forecast and actual cash flows and through the management of its capital structure. The Company continually revises its available liquid resources as compared to the timing of the payment of liabilities to manage its liquidity risk.

As at March 31, 2022, the Company had \$140,377 in cash and available revolving and swingline facilities.

The contractual undiscounted principal cash flows payable in respect of financial liabilities as at the date of these Interim Financial Statements, were as follows:

As at	March 31, 2022	December 31, 2021
	\$	\$
Amounts payable in more than 12 months	171,534	181,531
Amounts payable in less than 12 months	78,420	78,334
	249,954	259,865

Jamieson Wellness Inc.

Notes to the Unaudited Condensed Consolidated Interim Financial Statements

Three months ended March 31, 2022 and 2021

Impact of COVID-19

There is a continuing risk that COVID-19 may impact the results of operations or financial conditions. A new variant or strain may cause an outbreak within the Company's operating facilities, resulting in absenteeism or a plant closure for an extended duration. Suppliers may experience business disruptions that could impact the supply of raw materials or components required for production. Limitations on transportation or border closures may result in shipment delays from the Company's suppliers or to its customers.

The situation is dynamic and the duration and impact on the Company's business remain uncertain. The Company continues to review its safety protocols to reflect new government or public health recommendations. The Company has not benefited from nor applied for any government financial aid or relief relating to the COVID-19 pandemic.

Impact of Ukraine Conflict

The Company does not conduct any business operations in Russia or Ukraine. As the situation is fluid and changing rapidly, it is not possible to predict how the Ukraine conflict will affect global supply chains, commodity prices, the overall economic environment, or financial markets.

While the Ukraine conflict has no measurable disruption to the Company's supply of raw materials and its ability to service customers, the Company is actively monitoring for any potential impacts arising from it. The recent surge in gasoline prices has resulted in higher transportation costs for both inbound and outbound movement of goods. The continued risk surrounding the Ukraine conflict and any escalations may have a material adverse impact on the Company's business, its financial condition and results of operations.

Capital

The Company's objective is to maintain a cost-effective capital structure that supports its long-term growth strategy, supports the business and maximizes shareholder value. The Company typically uses leverage in its capital structure to reduce the cost of capital. The Company's goal is to maintain its primary credit ratios and leverage at levels that are designed to provide continued access to investment-grade credit pricing and terms.

The Company measures its credit profile using a number of metrics, some of which are non-IFRS measures, primarily cash, less long-term debt and bank indebtedness ("net cash (debt)") to earnings before interest, income taxes, depreciation, amortization, restructuring and other related costs, and interest coverage. Additionally, the Company maintains a cash flow reserve to service obligations as they come due.

In addition to credit facilities and equity, the Company uses leases as additional sources of financing.

There have been no material changes to the Company's risk management activities since the inception of the Company's operations.

The Company is subject to capital requirements under the credit facility agreement, as described in Note 5.

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three months ended March 31, 2022 and 2021

10. Segment information

The Company has two reportable operating segments with all material operations carried out in Canada:

- The Jamieson Brands segment's principal activity is the manufacturing, distribution and marketing of branded natural health products including vitamins, minerals and supplements; and
- The Strategic Partners segment's principal activity is providing contract manufacturing services to consumer health companies and retailers worldwide.

The Company's chief operating decision maker evaluates segment performance on the basis of earnings from operations, as reported to internal management, on a periodic basis.

Inter-segment revenues and expenses are eliminated upon consolidation and relate mainly to sales from the Strategic Partners segment to the Jamieson Brands segment.

	For the three month period ended March 31, 2022		
	Jamieson Brands	Strategic Partners	Total
	\$	\$	\$
Revenue	83,188	20,487	103,675
Earnings from operations	14,424	761	15,185
Foreign exchange loss			463
Interest expense and other financing costs			1,278
Provision for income taxes			3,703
Net earnings			9,741

	For the three month period ended March 31, 2021		
	Jamieson Brands	Strategic Partners	Total
	\$	\$	\$
Revenue	75,895	22,375	98,270
Earnings from operations	9,175	1,345	10,520
Foreign exchange loss			16
Interest expense and other financing costs			1,415
Provision for income taxes			2,953
Net earnings			6,136

Share-based compensation is allocated to the Jamieson Brands operating segment.

11. Revenue from contracts with customers

The following table sets forth the disaggregation of the Company's revenue from contracts with customers in the Jamieson Brands operating segment:

	Three months ended March 31,	
	2022	2021
	\$	\$
Domestic sales	69,696	64,007
International sales	13,492	11,888
Total revenue from contracts with customers	83,188	75,895

Jamieson Wellness Inc.
Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Three months ended March 31, 2022 and 2021

International sales are primarily denominated in U.S. dollars and subject to fluctuations in foreign exchange (see Note 9 – Financial instruments and risk management activities) on the conversion to Canadian dollars.

12. Earnings per share

Basic earnings per share amounts are calculated by dividing the net earnings attributable to common shareholders of the Company by the weighted average number of shares outstanding during the period.

Diluted earnings per share amounts are calculated by dividing the net earnings attributable to common shareholders of the Company by the weighted average number of shares outstanding during the period, adjusted for the effects of potentially dilutive share options, PSUs, RSUs and DSUs.

The following table sets forth the calculation of basic and diluted earnings per share:

Three months ended March 31,	2022			2021		
	Net earnings available to common shareholders	Weighted average number of shares	EPS \$	Net earnings available to common shareholders	Weighted average number of shares	EPS \$
<i>Basic</i>						
Continuing operations	9,741	40,442,265	0.24	6,136	39,889,792	0.15
<i>Diluted</i>						
Continuing operations	9,741	41,731,184	0.23	6,136	41,507,592	0.15